Table 3.
Between-group effects after 3 months of intervention *.
| Characteristics | CAST-CR Group versus AT-CR Group | Partial Eta Squared |
|---|---|---|
| MD (95% CI) | ||
| BMI (kg/m2) | 1.83 (0.43, 3.22) a | 0.26 |
| Waist Circumference (cm) | −1.99 (−5.23, 1.25) | 0.04 |
| Total Cholesterol (mg/dL) | −8.51 (−13.28, −3.75) a | 0.25 |
| HDL Cholesterol (mg/dL) | 5.94 (2.92, 8.97) a | 0.29 |
| LDL Cholesterol (mg/dL) | −6.76 (−10.95, −2.57) a | 0.22 |
| Triglycerides (mg/dL) | −11.90 (−19.36, −4.44) a | 0.21 |
| AST (U/L) | −5.70 (−8.82, −2.57) a | 0.26 |
| ALT (U/L) | −2.98 (−4.90, −1.06) a | 0.20 |
| SAT (cm) | −0.52 (−1.03, −0.01) | 0.15 |
| VAT (cm3) | −625.19 (−1151.76, −98.62) a | 0.23 |
| Fasting Glucose (Mmol/L) | −0.44 (−0.67, −0.20) a | 0.27 |
| Fasting Insulin (uIU/mL) | −0.32 (−0.91, 0.26) | 0.03 |
| HOMA-IR | −0.21 (−0.37, −0.05) a | 0.18 |
CAST-CR, concurrent aerobic and strength training with caloric restriction; AT-CR, aerobic training with caloric restriction; BMI, body mass index; HLD, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; HOMA-IR, homeostasis model assessment insulin resistance; MD, mean difference; CI, confidence interval; *, Data are mean ± SD; a significant p value between-group effects after 3 months of intervention, level of significance at p < 0.05.